Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622758 | 0.84 | ADORA1 (0.64) | ADORA1ADORA2ANR4A2KMT2AGAA | |
| SCHEMBL30160653 | 0.81 | ADORA1 (0.60) | ADORA1ADORA2AKMT2AGAAMAPT | |
| SCHEMBL13622766 | 0.81 | ADORA1 (0.60) | ADORA1ADORA2AKMT2AGAAMAPT | |
| SCHEMBL13622770 | 0.78 | ADORA1 (0.57) | ADORA1ADORA2ANR4A2KMT2AGAA | |
| SCHEMBL2960211 | 0.72 | ADORA1 (0.64) | ADORA1ADORA2ANR4A2KMT2AGAA | |
| SCHEMBL5371726 | 0.70 | KDM4E (0.46) | ADORA1ADORA2ANR4A2KMT2AGAA | |
| SCHEMBL26457583 | 0.70 | ADORA2A (0.49) | ADORA1ADORA2ANR4A2KMT2AGAA | |
| SCHEMBL31350484 | 0.70 | KDM4E (0.45) | NR4A2KMT2AGAAMAPTKDM4E | |
| SCHEMBL9379954 | 0.69 | CYP1A2 (0.58) | ADORA1NR4A2KMT2AGAAMAPT | |
| SCHEMBL6392289 | 0.69 | ADORA2A (0.47) | ADORA1ADORA2ANR4A2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR52 | ADORA1 220/4885ADORA2A 149/4885NR4A2 53/4885 |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | PIGS, GPR52, GPR174 | ADORA1 191/4885ADORA2A 203/4885NR4A2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.